Results 191 to 200 of about 1,629,755 (308)

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Translating laboratory quality management system into practice: strategic opportunities and challenges for ISO 15189:2022 implementation in Nigeria's healthcare system. [PDF]

Front Health Serv
Basil B, Okoro NI, Mba IN, Myke-Mbata BK.   +3 more
europepmc   +1 more source

The Professor in the Laboratory [PDF]

BMJ, 1951
openaire   +2 more sources

Laboratories of Democracy

JAMA Network Open, 2023
openaire   +2 more sources

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Global Performance of Human Papillomavirus Typing, Screening, and Evaluation As Assessed Using Proficiency Panels Traceable to International Standards: A Retrospective Analysis, 2008-2024. [PDF]

J Med Virol
Arroyo Mühr LS, Yilmaz E, Lagheden C, Eklund C, Dillner J.   +4 more
europepmc   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Different approaches to HIV confirmation: a survey of three Italian regions. [PDF]

Front Cell Infect Microbiol
Galli C, Regine V, Caraglia A, Centrone F, Chironna M, Cruschelli G, Farinella M, Moriconi S, Orlando VA, Pasqualini C, Puglia M, Pugliese L, Rancilio L, Tavoschi L, Voller F, Suligoi B.   +15 more
europepmc   +1 more source

ADP‐ribosylation: An emerging regulator of the epigenome

Molecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho, Chenqian Liu, W. Lee Kraus   +2 more
wiley   +1 more source

Knowledge and diagnostic practices for extensive recalcitrant dermatophytosis due to <i>Trichophyton indotineae</i>: A Franco-Belgian-Swiss survey of clinical microbiologists. [PDF]

New Microbes New Infect
Sacheli R, Ninet B, Botterel F, Hayette MP, Fontao L, Bosshard P, Desoubeaux G, Coste A, Brun S.   +8 more
europepmc   +1 more source